Drug intelligence / Profile preview

experimental vaccine 1

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics

Overview

"experimental vaccine 1" is a placeholder name used in clinical trials for different investigational vaccines. In one trial (NCT05408312), it refers to a GEN2-Recombinant COVID-19 Vaccine (CHO cells) being evaluated for safety and tolerability in healthy adults aged 18 and above. In another trial (NCT05645900), it refers to a Quadrivalent Influenza Virus Subunit Vaccine being assessed for safety and immunogenicity in Chinese children aged 6 to 35 months.

Beyond the preview

Go deeper on experimental vaccine 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on experimental vaccine 1.

Explore the full profile